This is a contrast between Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) and Oncolytics Biotech Inc. (NASDAQ:ONCY) based on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intercept Pharmaceuticals Inc.||179.80M||18.69||309.24M||-12.40||0.00|
|Oncolytics Biotech Inc.||N/A||0.00||N/A||-0.84||0.00|
In table 1 we can see Intercept Pharmaceuticals Inc. and Oncolytics Biotech Inc.’s top-line revenue, earnings per share and valuation.
Table 2 represents Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) and Oncolytics Biotech Inc. (NASDAQ:ONCY)’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Intercept Pharmaceuticals Inc.||-171.99%||-644.1%||-65.2%|
|Oncolytics Biotech Inc.||0.00%||-205.3%||-95.4%|
Volatility & Risk
Intercept Pharmaceuticals Inc.’s volatility measures that it’s 59.00% more volatile than Standard and Poor’s 500 due to its 1.59 beta. Oncolytics Biotech Inc. on the other hand, has 2.28 beta which makes it 128.00% more volatile compared to Standard and Poor’s 500.
Intercept Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 6 and 6 respectively. The Current Ratio and Quick Ratio of its competitor Oncolytics Biotech Inc. are 5.5 and 5.5 respectively. Intercept Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Oncolytics Biotech Inc.
Recommendations and Ratings for Intercept Pharmaceuticals Inc. and Oncolytics Biotech Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Intercept Pharmaceuticals Inc.||1||2||11||2.79|
|Oncolytics Biotech Inc.||0||0||0||0.00|
The consensus target price of Intercept Pharmaceuticals Inc. is $165.13, with potential upside of 45.90%.
Institutional and Insider Ownership
Intercept Pharmaceuticals Inc. and Oncolytics Biotech Inc. has shares owned by institutional investors as follows: 70.2% and 2.5%. Intercept Pharmaceuticals Inc.’s share owned by insiders are 23.2%. Insiders Competitively, owned 1.8% of Oncolytics Biotech Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Intercept Pharmaceuticals Inc.||11.04%||-13.29%||-8.26%||-4.36%||77.42%||3.82%|
|Oncolytics Biotech Inc.||-8.18%||-5.98%||-25%||-51.78%||-66.09%||8.56%|
For the past year Intercept Pharmaceuticals Inc.’s stock price has smaller growth than Oncolytics Biotech Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.